MS and Demyelinating Disorders

Lauren B. Krupp, MD considers how treatment failure in pediatric multiple sclerosis may be defined as disease relapse, new or enlarging legions, inability to tolerate treatment, or lack of adherence.

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed symptoms of MS that need more research, as well as other factors impacting care, such as comorbidities.

The rationale for initiating aggressive therapy early on to treat patients who present with relapsing-remitting multiple sclerosis.

An overview of the clinical subtypes of multiple sclerosis and factors that help neurologists distinguish between each type for an appropriate diagnosis.

Strategies for diagnosing and treating cognitive issues of multiple sclerosis during COVID-19.

Maintaining a healthy diet and exercise when combating multiple sclerosis.

Here's what is coming soon to NeurologyLive.

Researchers compared Neuro-QoL scores between patients treated with natalizumab and ocrelizumab, another high-efficacy treatment for MS.

The clinical research director at the UCSF Multiple Sclerosis Center discussed the findings of the long-term open-label assessment of inebilizumab in neuromyelitis optica spectrum disorder.

Neurology News Network for the week ending April 24, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 23, 2021.

The associate professor of neurology and neurologist at Duke University discussed the positive results of nipocalimab, a monoclonal antibody, in patients with myasthenia gravis.

Considerations regarding age in treatment decisions in patients with nonactive multiple sclerosis progression.

The therapy has fewer off-target effects on kinases and may be better-tolerated than other DHODH inhibitors for patients with relapsing MS.

Experts discuss how they monitor response to multiple sclerosis therapies and disease progression.

Patients in the randomized controlled trial and the open-label extension treated with inebilizumab experienced similar rates of being attack-free, extending as far as 4 years.

The professor of neurology and Neurological Sciences, Pediatrics, and Genetics at Stanford Medicine discussed the ULTIMATE trial data presented at the 2021 AAN Annual Meeting.

Patient/guardian decision, adverse event, and physician decision were the 3 noted reasons for discontinuation with either ofatumumab or teriflunomide.

Leaders in neurology provide insight into first-line disease-modifying therapies for relapsing-remitting multiple sclerosis, such as interferon or glatiramer acetate, and glucocorticoids for acute events.

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.

Richard shares his experience receiving his infusion therapy for treatment of multiple sclerosis.

An expert neurologist discusses treatment options for progressive multiple sclerosis.

Clyde E. Markowitz, MD, comments on the growing role of magnetic resonance imaging to help diagnose multiple sclerosis and highlights characteristics of lesions he looks at during a diagnostic evaluation.

Patricia K. Coyle, MD, highlights revisions to the McDonald diagnostic criteria for multiple sclerosis and emphasizes why health care professionals need to start referring to the criteria in a more standard fashion.

Here's what is coming soon to NeurologyLive.